Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Berman

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 22, 2021
Modeling autosomal dominant Alzheimer's disease with machine learningPatrick H Luckett, Austin McCullough, Brian A Gordon, et al.
Brain : a Journal of Neurology|May 17, 2022
Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiologyJohn C Morris, Michael Weiner, Chengjie Xiong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2025
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathologyEric M McDade, Nicolas R Barthélemy, Guoqiao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Brain : a Journal of Neurology|February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onsetHaiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Acta Neuropathologica|June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer diseaseCharles D Chen, Erin E Franklin, Yan Li, et al.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Neurology|January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 22, 2021
Modeling autosomal dominant Alzheimer's disease with machine learningPatrick H Luckett, Austin McCullough, Brian A Gordon, et al.
Brain : a Journal of Neurology|May 17, 2022
Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiologyJohn C Morris, Michael Weiner, Chengjie Xiong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2025
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathologyEric M McDade, Nicolas R Barthélemy, Guoqiao Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Brain : a Journal of Neurology|February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onsetHaiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Acta Neuropathologica|June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer diseaseCharles D Chen, Erin E Franklin, Yan Li, et al.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Neurology|January 26, 2021
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Guoqiao Wang, Kejal Kantarci, et al.
Pageof 8